LOS
ANGELES, Oct. 5, 2023 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR pathway alterations, today announced that two
posters will be presented at the upcoming North
American Neuroendocrine Tumor Society (NANETS)
Multidisciplinary NET Medical Symposium, taking place October
4-6, 2023, in Montreal, Canada.
Details of the poster presentations are below:
Title: "Phase 2 study of nab-sirolimus in
patients with well-differentiated and advanced or metastatic
neuroendocrine tumors of the gastrointestinal tract, lung, or
pancreas"
Date/Time: Thursday, October 5, 2023, 5:15 pm – 7:00 pm
EDT
Presentation Location: Poster Gallery Location, Square
Dorchester
Presenter: Scott Paulson, MD
Authors: Michael J. Demeure, MD; Allen L. Cohn, MD; Tara
Seery, MD; Li Ding, MS, MA;
Usman Aziz, MD; Willis Navarro, MD; Scott Paulson, MD
Highlights:
- The PI3K/AKT/mTOR pathway has been implicated in the
pathogenesis and progression of NETs, though the use of oral mTORis
as a treatment for NETs is limited by low bioavailability and the
heterogeneity of the disease
- nab-Sirolimus is a nanoparticle albumin-bound mTORi
designed to preferentially target tumors and overcome the
limitations of oral sirolimus
- nab-Sirolimus is currently approved in the United States for the treatment of
malignant perivascular epithelioid cell neoplasms
- The efficacy and safety of nab-sirolimus in patients
with advanced or metastatic NETs will be evaluated in this phase 2,
multicenter, open-label, single-arm, US-based study
- The study, NET-202 (NCT05997056), will enroll up to 21 efficacy
evaluable patients at approximately three US centers. Enrollment
for the study is planned to begin in the third quarter of 2023,
with completion expected within 12–18 months
An encore presentation titled, "Phase 2, Multicenter,
Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors
Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2
(PRECISION1)" will also be presented on Thursday, October
5, 2023.
More information can be found on the North American
Neuroendocrine Tumor Society (NANETS) website.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies to bring transformational therapies to
cancer patients with mTOR pathway driver alterations. Aadi received
FDA approval in November 2021, and in February 2022 commenced commercialization of
FYARRO® for the treatment of adult patients with locally
advanced unresectable or metastatic malignant perivascular
epithelioid cell tumor (PEComa).
Aadi is conducting the PRECISION1 trial, a Phase 2
tumor-agnostic registration-directed study in patients with
mTOR inhibitor-naïve malignant solid tumors harboring
TSC1/TSC2 inactivating alterations. More information on
Aadi's development pipeline is available on the Aadi
website at www.aadibio.com and connect with us
on Twitter and LinkedIn.
Contact:
Marcy
Graham
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-announces-poster-presentations-at-the-north-american-neuroendocrine-tumor-society-nanets-2023-multidisciplinary-net-medical-symposium-301948926.html
SOURCE Aadi Bioscience